Corrections

Hungary's treatment route out of punishment covers only use, or a small quantity for one's own use; this entry had described it as open to anyone who met its conditions. The route is also closed to anyone found guilty of drug trafficking or possession in the previous two years, which the entry had left out. The entry now gives the penalty for handing over a small quantity and the heaviest terms, up to twenty years for the largest amounts and life for trafficking, and says no mushroom appears in the drug schedule.

Japan's health ministry said in April 2002, before the designation of the mushrooms took effect on 6 June 2002, that it would name no species; this entry had dated the statement to the designation. In the law section, 1 October 2026 and 6 September 2026 are the dates of the versions read; the Act dates from 1953 and the Order from 1990. The entry now gives the prison terms for offenses committed for profit, and a sentence on a clinical study is no longer printed.

This entry had called using or holding psilocybin for personal use in Luxembourg a crime. Its penalty, eight days to six months in prison, is a correctional one, which makes the offense a délit; the entry now calls it an offense, and the penalty is unchanged. The 2004 wording that named plants and mushrooms was an earlier text of the same paragraph of the 1974 regulation, replaced in 2009; the entry had called it a predecessor. The entry now gives the heavier prison terms for growing, importing and supply, up to life, and its head sentence gives one to five years for growing, even for personal use.

In Malta no conviction for possession for personal use, in any court, appears on a conduct certificate; this entry had tied that rule to convictions before a Commissioner for Justice alone. The entry now names the Commissioners for Justice Act as the source of the words "shall not cease to be a criminal offence". The head sentence now gives up to ten years for more than two grams, and the entry adds that dealing, which includes cultivation and supply, can bring life imprisonment.

In Slovakia a negligible amount of psilocybin mushrooms is anything up to 10 grams dried, or more where it holds no more than 100 milligrams of active substance. This entry had said the active substance decides the tiers above 10 grams; the Criminal Code sets them as multiples of that weight. It had also placed section 10(2), on acts too minor to be crimes, in the Misdemeanours Act; the section is in the Criminal Code. The entry now gives the terms for production and trafficking, up to life, and the conditions of the court waivers.

Denmark's entry now cites the executive order that lists controlled substances. It had cited a Medicines Agency page that links to the lists and does not itself name psilocybin. The order, in force since 29 March 2026, lists psilocin, psilocybin and mushrooms and spores that contain either. Neither the law nor the entry's status changes.

Estonia's planned change to drug penalties is a ministry intent document of January 2026. This entry had called it a draft amendment under consultation. As of 10 Nov 2026 no bill on it is in parliament's register of drafts.

Jamaica's Dangerous Drugs Act is silent on psilocybin, but that is not the whole legal position. The Food and Drugs Act governs products sold as drugs. This entry's summary had said the silence was everything.

Alaska's psychedelics ballot initiative was not on the 2026 ballot, and its filing deadline of September 14, 2026 has passed. The Division of Elections' page, as archived on October 24, 2026, shows no filing. Two parts of this entry had disagreed, one calling the initiative active and one calling it failed.

Arizona's SB 1542 of 2026 would have appropriated $10 million for MDMA trials and training, as well as extending workers' compensation. An earlier correction here said it appropriated nothing. The bill was held in committee. SB 1555 was signed on June 27, 2025; one line had said April 22.

Colorado issued its first healing center license on March 31, 2025. A history line had said centers opened in January 2025. The Natural Medicine Division sits in the Department of Revenue; two history lines had named DORA.

Connecticut's pilot is to be administered by a medical school in the state. Parts of this entry had said a state medical school, which the act does not require.

Georgia's HB 717 was signed on May 12, 2026, and HB 382 waits on a DEA scheduling step as well as FDA approval. Parts of this entry had said May 25 and had named an unrelated bill.

A ballot initiative or a Board of Pharmacy rule, as well as the Legislature, could change psilocybin's status in Idaho. One answer had named only the Legislature.

Indiana funded its psilocybin research fund the year after creating it, in the 2025 budget. This entry had said two years later.

LD 1034 was a bill of Maine's 132nd Legislature. Two lines of this entry had said the 131st.

Maryland law does touch psilocybin research. A researcher registered federally for Schedule I work must give the state health department evidence of that registration. This entry had said state law does not govern the research.

The pilot the Massachusetts House passed inside H.5576 in July 2026 is a different program from the five-site pilot in H.4986. This entry had described them as one. Its summary had also called the local resolutions the lowest enforcement priority, where the one read says among the lowest.

Psilocybin possession in Michigan is punishable by up to a year in jail, a $2,000 fine, or both. Parts of this entry had dropped the words or both. The entry also no longer says a statewide ballot initiative is being pursued: none is on the state's petition list for 2025-2026.

Minnesota's psilocybin bill HF 2906 did not reach a floor vote before the legislature adjourned on May 18, 2026. Parts of this entry still described it as pending.

Mississippi's entry now cites the 2026 state law that reprints the Schedule I list, where psilocybin and psilocyn appear. It had cited the legislative history of the state's ibogaine research law, and that history does not mention psilocybin. Neither the law nor the entry's status changes.

Parts of Missouri's entry still called the 2026 psilocybin study bill's fate unconfirmed. It was still on the Senate's informal calendar at 6 p.m. on May 15, 2026, when Missouri's constitution tables every bill left on a calendar.

In Nebraska, manufacturing or distributing psilocybin is a Class IIA felony. Parts of this entry had said Class II. Possession is a Class IV felony.

Nevada's SJR 10, which urges Congress to fund psychedelic research, was adopted in 2025 and is not a pending proposal. This entry had listed it under proposed laws.

New Hampshire's HB 528 passed the House in March 2025 and did not pass the Senate, so no penalty changed. This entry's summary had said it cut penalties.

New Mexico's patient and clinician rule, 7.35.3 NMAC, was still listed as pending on 10 Nov 2026. Parts of this entry had carried two different dates for that check.

North Dakota's law already lists the psilocybin product COMP360 in Schedule IV, with no condition attached. Parts of this entry had said the listing waits on FDA approval. The FDA has not approved the product, and psilocybin in every other form stays in Schedule I.

Oklahoma's HB 4293 would have authorized ibogaine research and did not advance past committee. One sentence had said it would direct the research. HB 3834 took effect on November 1, 2026.

Pennsylvania's entry now cites the state regulation that lists psilocybin and psilocyn as Schedule I substances. It had cited the page of a pending bill. Neither the law nor the entry's status changes.

Rhode Island's entry still cited a repealed section, said the House had passed psilocybin bills in several sessions when it passed one, in 2023, and said the 2026 bill H 7756 received a hearing that the General Assembly's records do not show.

Two 2025-2026 South Carolina bills do name psilocybin, S 1039 and H 5397. Both would keep it in Schedule I, and neither has left committee. This entry had said no psilocybin bill was found.

South Dakota's HB 1099 turns on FDA approval alone. Parts of this entry had said it also waits on a DEA rescheduling, which the act does not mention.

Utah's 2026 session passed two more bills touching the psilocybin treatment law, HB 279 and HB 301, which one field had left out. The law is repealed on July 1, 2027, and no record shows a program operating under it.

Virginia's trigger laws were signed on April 6, 2026; one answer still said April 8. The entry also dated a failed advisory-council bill, SB 1101, to 2026 when it was a 2025 bill, and described the acts' wording loosely.

West Virginia's psilocybin law waits on two federal steps, FDA approval and DEA rescheduling. This entry's opening sentence had named only the FDA.

D.C. law makes entheogen offenses among the police department's lowest enforcement priorities. Parts of this entry had said the lowest.

Puerto Rico's 2026 executive order orders a capacity strategy and a feasibility study of a research pilot. One answer had said it tells the health department to prepare the island for trials.

Chile's entry now rests on the scheduling decree itself. Decreto 867 lists psilocybin and psilocin, and names the Psilocybe mushroom among the species covered by the cultivation offence. The decree has not been amended since September 2023. Chile's status is unchanged.

Colombia's entry now shows that a Senate bill on seizing personal doses of drugs has moved one step: its first-debate report is filed and awaits discussion in committee. The bill has not been debated or passed. Colombia's status is unchanged.

Czechia's entry now cites the regulation for its dose limits on medical psilocybin, which it had taken from press reports: at most 75 mg in a calendar month, at most 35 mg in a single dose, and at least seven days between doses. The regulation has not been amended since it took effect on 1 January 2026.

Estonia's entry now names the schedule that lists psilocybin. The government re-issued its list of controlled substances on 6 August 2026, and psilocybin and psilocin, including mushrooms that contain them, are in Schedule I. The penalties described here are unchanged.

A law of 18 August 2026 raised France's on-the-spot fine for drug use from 200 euros to 500 euros. The reduced amount is now 400 euros and the increased amount 1,000 euros. Courts may also suspend a driving licence for up to three years after any drug-use conviction. This entry printed the old amounts until this correction. The fine remains a criminal penalty, and France's status is unchanged.

Latvia's entry now records that a February 2026 amendment to its drug circulation law left the possession rule alone. Having a small amount of a controlled drug without authorisation, or using one, still draws a warning or a fine of 10 to 56 fine units. Latvia's status is unchanged.

Mexico's entry now lists a January 2026 initiative in the Chamber of Deputies that would move psilocybin and psilocin into a class of substances recognised as having therapeutic value. It was sent to the Health Committee and has not been enacted. Psilocybin remains illegal in Mexico.

Norway's entry now cites the latest amendment to its narcotics regulation, in force from 1 September 2026. The regulation's list still includes psilocybin, psilocin and Psilocybe mushrooms. Psilocybin remains illegal in Norway.

Uruguay's entry now cites the article that defines which substances its drug law covers. Article 1 of Decreto-Ley 14.294 applies the law to the substances in List I of the 1971 Convention on Psychotropic Substances. The law itself has not changed.

A bill introduced in the House on 29 October 2026 has been added to this entry. H.R. 10923 would set up a new federal drug scheduling system, hand scheduling decisions to the health secretary, and require a review of 32 substances within two years, psilocybin and psilocin among them. If that review were missed, the bill would place both in schedule IV of the new system. It has only been referred to committee, and psilocybin's legal status is unchanged.

Missouri's entry now records a second 2026 bill that carried psilocybin language. A public safety bill, HBs 3068 and 3049, would have shielded veterans and first responders enrolled in a psilocybin study from state penalties. The House passed it in April 2026 and it went no further than a Senate committee. Psilocybin remains illegal in Missouri.

Oregon's entry now lists a second 2026 law that amends its psilocybin statute. From 1 January 2027 a farm store cannot be run alongside a crop of psilocybin-producing fungi on land zoned for exclusive farm use, a limit that already applies to farm stands and new dwellings. The law was approved on 7 April 2026. Access to psilocybin services is unchanged.

Utah's entry now names the 2026 law that widened its hospital psilocybin provision. HB 279, signed on 19 March 2026, added healthcare systems closely affiliated with a private postsecondary institution to those that may run a treatment program using psilocybin that is in Phase 3 FDA testing. The entry had credited only the act that renumbered the section. Utah's status is unchanged.

Ireland's entry now gives the right stage for a 2017 bill that would decriminalise possessing drugs for personal use. It was taken at Second Stage in the Seanad on 4 March 2025 and has not moved to Committee Stage, as this entry had said. Psilocybin remains illegal in Ireland.

North Macedonia's entry now cites the 2023 gazette issue that added the rule it rests on: a person who holds drugs for personal use is not to be punished. It keeps the 2009 issue it cited before as the source for the prison ranges for supplying drugs, and neither the law nor the entry's status changes.

Our Massachusetts entry now cites the state law it rests on, which lists psilocybin and psilocyn as Class C controlled substances, and the state's official results for the 2024 ballot question on natural psychedelics, which voters rejected by 1,902,513 votes to 1,444,797. It had cited a pending bill, and neither the law nor the entry's status changes.

Correction. HB 4040's changes to Oregon's psilocybin program take effect on 1 January 2027, and this entry had described one of them as already in force. From that date occupational and physical therapy licensees who also hold a facilitator license may combine preparation and integration sessions with their therapy work, and training from another state's approved program can count toward an Oregon facilitator license. Oregon's legal status is unchanged.

California is now recorded as illegal. Possessing psilocybin is a misdemeanor under state law, punishable by up to a year in county jail, and our earlier reading rested on six city resolutions that lower local enforcement priority and are no defense in a state prosecution.

Massachusetts is now recorded as illegal. Possessing psilocybin is a crime under state law, punishable by up to a year in jail, and our earlier reading rested on eight municipal resolutions that make it the lowest local enforcement priority, which change no state law.

Michigan is now recorded as illegal. Possessing psilocybin is a misdemeanor under state law, punishable by up to a year in jail or a $2,000 fine, and our earlier reading rested on six city and county resolutions that lower local enforcement priority, which change no state law.

Washington is now recorded as mixed. Possessing psilocybin is still a gross misdemeanor statewide, and our earlier reading rested on five city and county resolutions that ask local police to make enforcement their lowest priority, which change no state law. The state also funds a University of Washington pilot that offers psilocybin therapy only through FDA-approved pathways.

Canada's entry said nobody in Canada buys psilocybin legally, no license to sell it has ever existed, and a doctor asks for an individual section 56 exemption. Health Canada's pages and the Controlled Substances Regulations say otherwise. Under the Special Access Program the manufacturer sets the price and in some cases the patient or their family pays, licensed dealers sell to practitioners named in a letter of authorization, and patients apply for section 56 exemptions themselves, with a practitioner's support. The entry also dated the Federal Court of Appeal's judgment in Toth v Canada, 2025 FCA 119, to 26 June 2025; the judgment was delivered on 18 June 2025. Its account of the case now sits under History, without four details that the judgment does not bear out as written or that no source confirms.

Correction. An update published here on 14 September 2026 said written comments to the FDA about its public hearing on psychedelic medicines could be sent until 6 October 2026. The deadline was 11:59 p.m. Eastern on 5 October 2026, as the hearing notice and the FDA's meeting page both say; the date we published came from a database field kept in universal time, which runs four hours ahead of Eastern time. The same update said the hearing took place on 14 September without citing a source. The FDA's own recording of its live webcast shows that it did. Nothing about federal law has changed.

Correction. An update dated 15 September 2026 recorded the fees in Oregon's proposed psilocybin rules, among them a facilitator licence rising from $2,000 to $4,000 a year and service center and manufacturer licences rising to $20,000. Those amounts were already public in the proposed rule text Oregon filed with the Secretary of State on 28 August 2026, which an earlier update records; 15 September was the day of the first public hearing and the day the figures reached us. Oregon has since dropped the increases, and its legal status is unchanged.

Correction. Canada's entry said that since 1 October 2026 the Special Access Programme route had "a new legal footing", and that access continues under the new Controlled Substances Regulations. That claimed too much. The Programme's letter of authorization is still issued under the Food and Drug Regulations, as it was before. What the new regulations supply since 1 October is the authority for what the practitioner and the licensed dealer named in that letter may do with the drug. Until then that part was covered only by an exemption dating from January 2022.

A pending Senate bill that names psilocybin has been added to this entry. S. 4031 would have the Department of Veterans Affairs designate at least five centers of excellence for therapies that include psilocybin. It was introduced in March 2026, has not moved out of committee, and does not change psilocybin's legal status.

New Mexico's entry is corrected on two points. Applications are open for psilocybin growers but had not yet opened for testing laboratories when the Department last posted, on 18 September 2026. The hearing on the proposed patient rule was set for 2 October 2026, and the Department had published nothing further by 5 October. Patients still cannot enroll.

In Alaska, possessing psilocybin is a class A misdemeanor, a class C felony after a conviction within 10 years, and a class B felony even on a first offense near a school or youth center or on a school bus.

In Florida, selling psilocybin is the same third-degree felony as possessing it, except near schools and other listed places or when an adult sells to a minor. An earlier version said sale and trafficking carry steeper penalties.

In Illinois, possessing any amount of psilocybin is a Class 4 felony whatever the quantity; the heavier classes by weight apply to manufacture and delivery.

Possessing any amount of psilocybin in New York is at least a class A misdemeanor, and 25 milligrams or more is a class C felony. An earlier version said any quantity was a misdemeanor.

HB 1802 (2021) became law without the governor's signature, directed a study for veterans with PTSD, not depression, and expired on September 1, 2025. An earlier version called the study both expired and ongoing.

The United Kingdom entry no longer says research licensing was eased in 2025. Ministers agreed to a pilot in principle and have not yet changed the rules. Psilocybin mushrooms remain Class A.

Michigan's entry now cites the section of state law that actually lists psilocybin in Schedule 1, and separately the penalty for using it. Nothing about the state's status has changed.

A note on method for the entry of 22 September 2026: the Oregon Health Authority statement it reports was read in full on 28 September 2026, as the HTML its web page served. Nothing in that entry changes, and Oregon's legal status is unchanged.

Rhode Island's entry now cites the law in force. The state repealed its own drug schedule in February 2025 and since then has controlled every substance on the federal list, where psilocybin remains in Schedule I. Its legal status is unchanged.

Utah's entry now cites the renumbered sections of the state's drug law, and says when the overdue-report finding was last seen, since the registry that showed it can no longer be reached. The hospital-based psilocybin authorization is unchanged.

Canada's entry was reviewed before new federal regulations take effect on 1 October 2026, and two details were corrected. The regulations were registered on 28 November 2025, not 17 December, which is when they were published. And the regulations do not themselves cancel the exemption that links psilocybin to the Special Access Programme: Health Canada has said it will do that on the same day. The route continues under the new regulations, and individual section 56 exemptions are unaffected. We will check again once 1 October has passed.

Ecuador's entry now cites a government source for the first time: article 364 of the Constitution, in the National Assembly's own text, which bars criminalizing people who use drugs. The decree that repealed the possession thresholds, the criminal code articles and the 2023 court resolution are still not sourced to a government document, and the entry says so.

This entry no longer says that wellness clinics were planned for patients in Saint Vincent and the Grenadines. Nothing we can cite supported it. We also checked the right part of the government this time: the Bureau of Standards named as the licence issuer sits under the Ministry of Agriculture, whose website we had never searched. On 21 September 2026 it returned nothing for psilocybin, nothing for psychedelic and nothing for the companies named in the announcements, while returning results for arrowroot and for the Bureau itself. The country's legal status here is unchanged, and so is our low confidence in it.

An update published here on 17 August 2026 described the Department of Health's psilocybin programme page as one that had not been updated. That judgement was reached by measuring the page's underlying code, which never contains its announcements: those are loaded from another service when a reader opens the page. Read in a browser today, the panel carries dated departmental notices going back to June 2026, including the opening of producer applications and the notice of the 2 October hearing. We cannot say what it displayed back in August, because the panel keeps no history of its own changes. The sources this record relies on do not change, and New Mexico's legal status is unchanged.

This entry said a 2023 decree ended police fines for drug use in Colombia. It did not: the decree repealed a police procedure, and the Police Code still fines consuming drugs near schools, in parks and in other public places, within limits the Constitutional Court has set. The entry also now explains which court rulings protect a psilocybin user.

The entry now names the Colombian law that lists psilocybin, Ley 43 de 1980, and dates the 2026 Ministry of Health resolution that keeps it on the national list.

The entry now lists a Senate bill that would provide for the seizure and destruction of drugs, including the personal dose.

This entry described possession for personal use in Costa Rica as lawful. It is not: the drug statute sets no criminal penalty for it, but the law still treats drug use as illicit. The wording is corrected. The rest of the entry, including the absence of any quantity threshold, was re-checked against the statute and stands.

Costa Rica's drug law is now cited by its correct name, Ley 7786 as rewritten in full by Ley 8204 in 2002, with a link to the current official text. This entry also names the article of the General Health Law that prohibits personal drug use, and now says that growing or producing drugs is punished whatever the purpose, and that the treatment article covers minors in private places as well.

Costa Rica's official list of controlled substances names the compounds psilocybin and psilocin and has no entry for mushrooms, and this entry now says so.

Italy's entry was corrected. It had described the 2006 health ministry decree as setting a daily limit for psilocybin and psilocin and none for the mushrooms. The decree sets a threshold of 300 mg each, worked out from an average single dose, and measures mushrooms by the psilocybin and psilocin they contain; the entry now also cites the 2014 decree-law that put that decree back into effect after the Constitutional Court's judgment that year. The legal status is unchanged.

Portugal changed its rule on drug quantities in October 2023, and this entry had not caught up. The 10-day supply is no longer a hard limit. Carrying more is treated as a sign the drugs may not be for personal use, and once personal use is shown, the case still goes to a Dissuasion Commission. The entry now says so and cites Law 55/2023.

The entry now names where Portuguese law lists psilocybin: Table II-A of Decree-Law 15/93, republished in May 2026. It also notes that Portugal's official table of average daily doses, a reference for what counts as a 10-day supply, gives no figure for psilocybin.

The entry now lists two bills before Portugal's parliament that would tighten the 2023 possession rule for all drugs, including psilocybin. Neither has had a plenary vote.

Maryland's Schedule I keeps no list of drugs of its own. It takes in whatever the federal government schedules, and that is how psilocybin is controlled here. The record now says so, and names the sections that make possession and distribution offences.

An update published here on 25 August 2026 said New Mexico had until the end of 2026 to have its medical psilocybin programme running. The Medical Psilocybin Act sets one implementation date and it is 31 December 2027. December 2026 is the date the Department of Health has said it aims for, and this record's law section has always described it that way. New Mexico's legal status is unchanged and no date in that law section moves.

Two Oregon licensing figures are corrected. The state approved 377 facilitator licences and 25 service center licences during 2025, and those figures count approvals granted across the year. They are not a roster of licences held at its end, and the health authority publishes no year end count. How many people received services is unchanged, at 5,935 in 2025 and 952 in the first quarter of 2026. Oregon's legal status is unchanged.

The federal record's notes were corrected. The April executive order's rescheduling review attaches only once a drug completes Phase 3 trials for a serious mental health disorder, and it sets no deadline; the earlier wording read as an overdue action. DEA rescheduling actions published since the order concern marijuana products and three insomnia drugs and do not mention it. Document counts were updated as of 1 September 2026. The legal status is unchanged.

New Mexico's record was wrong about how far the state had got, and this corrects it. The rule that licenses psilocybin growers and testing laboratories was not still a proposal: it took effect on 23 June 2026, which is why the Department of Health was able to start taking applications from growers in August. The rule covering patients, clinicians, facilitators and healing centres has come back from being cancelled and now has a public hearing set for 2 October 2026. New Mexico can license a grower today, but still not a clinician and still not a patient.

Croatia's record gave one to twelve years for selling. A November 2025 amendment raised the minimum to three, and the entry published in August had missed it. The possession fine is now shown in euro, the currency it is actually imposed in. The record also now says that a first offence can be met with treatment instead of a fine, and that giving mushrooms to someone else is a separate crime.

Croatia's record cited the wrong law. The 2011 Criminal Code it pointed to still made possession a crime; the act that changed that was a 2012 amendment. Both cited sources are now the official gazette texts that do the work. The decriminalized status is unchanged.

Two penalty corrections. The one to twelve year sentence covers selling, not growing, which carries six months to five years. The possession fine comes from a different act and is set in kuna, so the euro figure shown before was low. The record now also states that growing mushrooms counts as producing a drug.

Removed an unverified patient count and a related safety statement from this entry. No official Australian publication supports them; the regulator releases scheme data only through freedom of information disclosures, which this register has not yet read. The scheme's legal status is unchanged.

Brazil's entry now explains what the drug statute actually does. It prohibits no substance by name; it defines a drug as whatever appears on a list kept by the health agency, which is why an unlisted mushroom containing a listed molecule is a genuinely contested question there. The entry also now says that possession, and growing for personal use, carry no prison sentence in Brazil. The status is unchanged.

Australia's entry now names the provisions that actually limit prescribing, Appendix D clause 9 of the Poisons Standard and subsection 19(5) of the Therapeutic Goods Act, and records an application to allow psilocybine for existential distress at the end of life. A delegate decided on 29 May 2026 that the current scheduling remains appropriate, and a final decision is still to come. Psilocybin remains prescribable only by an authorised psychiatrist and only for treatment-resistant depression.

Denmark's entry pointed at an executive order that stopped being current in 2020. The order in force is now cited, and the listing itself is unchanged: mushrooms and their spores have been controlled since 2001.

North Macedonia's entry had no official source and applied one article's prison range to two different offenses. The gazette has now been read: the range belongs to the supply offense, the separate offense of enabling use carries one to five years, and a 2023 amendment says a person holding drugs for personal use is not to be punished.

Norway's entry said the 2025 drug reform was in effect. It is not: the Act has passed and been promulgated, but commencement is left to the King and has not been set, so nothing in it has started.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

California's 2025 research law is broader and shorter-lived than this entry said. AB 1103 speeds up state review of research using any Schedule I or Schedule II drug, psilocybin among them, rather than psychedelics specifically, and the fast-track expires on 1 January 2028.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

Indiana's psilocybin research fund is funded at $300,000 a year, $600,000 over the two-year budget, and the money comes from the state's opioid settlement account rather than general tax revenue. The amount and its source are now recorded from the budget act itself.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

A note on this record said no psilocybin legislation had been found here. That was wrong: this state does schedule psilocybin and the law is cited on the record. What was meant is that no reform law has passed.

Argentina's entry now cites the instrument that actually lists psilocybin. The statute it cited before, Law 23.737, never names the substance: it defines controlled drugs by reference to lists that the executive sets by decree, and the decree in force is Decree 122/2026.

Armenia's entry now cites the articles that actually carry the law: Article 396 of the 2021 Criminal Code for the criminal tier and Article 44.1 of the Code of Administrative Offences for the administrative one, replacing an insider-dealing article and an article repealed in 2004. The government decision that lists psilocin and psilocybin is cited for the first time, and the penalty range is restated from the statute.

Canada's entry now cites the regulation that actually carries the 1 October 2026 date, and corrects what it said would happen next. The exemption is being folded into new regulations rather than simply ending, so the Special Access Programme route is carried forward past that date.

Czechia's entry now cites a version of the law that can be read and checked, and records a limit it had missed: treatment is confined to psychiatric hospitals run directly by the Ministry of Health, and any other facility needs a permit.

Germany's entry was a year out of date. The regulator lists one psilocybin programme, running from 18 June 2026 to 17 June 2027 at a single institute in Mannheim for treatment-resistant depression, and the entry now says that instead of describing a national scheme.

Nepal's entry no longer says only that the law is evolving. It now states what the Narcotic Drugs (Control) Act actually lists, cites the government's own consolidated text and the drug regulator's import list, and explains that psilocybin's position rests on being left out of both rather than on any permission.

The Netherlands entry no longer says truffles are sold in licensed smart shops or that they were explicitly excluded from the 2008 ban. The Opium Act contains no smart-shop licence and never mentions truffles at all, so they fall outside it rather than being carved out of it.

Switzerland's entry now cites the schedule that actually names psilocybin, rather than resting only on the Narcotics Act article, which does not. Nothing about the law itself has changed.

Thailand's entry now carries the full set of penalties the Thai FDA publishes, including the fine attached to the five year term and the separate commercial and distribution band it had omitted. Nothing in Thai law has moved; the widely repeated 2026 reform claims trace only to content farms.

Arizona's trigger law was signed on 27 June 2025, not in April, and the provision that would allow psilocybin to be prescribed sits at a different section of the code than the entry named. Both are corrected from the enacted chapter text. The law itself is unchanged and still does nothing today.

Colorado's entry no longer calls healing centers 'in development': state-licensed centers have been operating since 2025.

Connecticut's entry now cites the text of the act itself rather than a bill tracking page that never mentioned psilocybin. Nothing about the law changed; the citation now supports what the entry says.

Louisiana's psychedelic-assisted therapy initiative is law and has been in force since 1 August 2026. The entry still described it as a bill awaiting the governor's signature.

Minnesota did enact psilocybin language in 2026 after all. It is not access: a cannabis act signed in May requires the state to publish a report by 15 January 2027 on how a psilocybin therapeutic use program could work. We had recorded that no psilocybin provision passed.

Montana's entry now says when its no-pending-legislation claim was last checked: the 1 Aug 2026 review. The legislature meets in odd-numbered years, so nothing can advance in regular session this year.

New Mexico's record now cites the rulemaking page rather than a programme page that has not been updated, and says plainly that the producer and laboratory rule is only proposed and the patient and practitioner rule was canceled and is to be rescheduled. The 2026 budget act, signed in March, is added: it funds the treatment equity fund and a university research programme and gives the Health Department another year to spend its 2025 start-up money.

Ohio's entry now dates its no-bills-with-movement claim to the 16 Aug 2026 review. The one cited proposal, listed as HB 249 of 2025, still shows no committee movement.

Oregon's entry now cites the session law rather than a bill overview page that did not carry the dates the entry published. The facts are the same; the citation now proves them.

Utah's entry overstated two things. The law allows a wider class of health systems than we described, following a 2026 renumbering, and we called the pilot operational when no state record shows that it is. The report the Legislature required by 1 July 2026 is registered as overdue and unfiled.

The British Virgin Islands entry now says plainly which part of its reading is ours. The statute lists psilocin; the view that unlisted fresh mushrooms leave a real ambiguity comes from comparing the territory's law to England before 2005, and no local instrument or court has said it. Confidence has been lowered accordingly.

Pakistan's entry quoted a Schedule-I heading that does not appear in the Act, and cut off its quotation of section 6 one clause early. Both are corrected against the Government of Pakistan's own consolidated text, which also carries a 2022 amendment the entry had never mentioned. Psilocybin's listing itself is confirmed.

Australia's entry now cites the national Poisons Standard rather than a Victorian state page. What the law says is unchanged.

Belgium's entry pointed at the wrong article for the probation route open to people caught with drugs for their own use. It is article 9, not article 9bis, and the entry now says so. The penalties are unchanged.

Bolivia's entry now cites Bolivia's own official consolidated law rather than a third-party database, and names the 2017 law whose list actually covers psilocybin. A cultivation penalty the entry had cited rests on a cross-reference repealed in 2017 and has been removed. Psilocybin remains illegal.

Brazil's entry now cites the version of the controlled-substances list actually in force, and records that in August 2025 the Superior Court of Justice held that selling psilocybin mushrooms is drug trafficking even though the mushroom itself is not on the list. The status is unchanged.

Canada's entry now shows that the exemption connecting psilocybin to the Special Access Programme is revoked on 1 October 2026. The route is open until then.

Czechia's entry now cites the adopted regulation rather than the draft that was notified to the EU, and records which specialists may prescribe.

Denmark's entry said no bill was pending. A resolution proposal on psychedelics, B 5, had in fact been tabled and then lapsed when the session ended in March 2026, and the entry now records it. The list of banned substances also covers spores, which the entry had not mentioned.

Finland's entry had no primary source behind it. The Narcotics Act and the decree that lists psilocybin are now cited directly, and both say what the entry already said.

France's entry quoted a 500 euro fixed fine that was announced but never enacted. The statute sets 200 euros, reduced to 150 and raised to 450, and the entry now matches it.

Jamaica's entry is flagged as not yet checked against the text of the Dangerous Drugs Act. What it says is unchanged; how confident the register is in it has been lowered.

Jamaica's entry has now been checked against the text of the Dangerous Drugs Act itself, which was the outstanding task. Neither the Act nor its regulations mentions psilocybin or mushrooms anywhere, so the status stands and confidence has been restored. The entry now says plainly that this is legality by omission, not an approved programme.

Lithuania's entry rested on a European agency summary and said the administrative route had been abolished in 2017. Using drugs without a prescription is still an administrative offence there; it is possession that is criminal. The entry now cites the Criminal Code and the substance list directly, and records that spores are covered.

Mexico's entry was checked line by line against the two statutes in force and everything it says about the law holds. One correction: a Senate initiative it described was presented in 2023, not 2024, and the entry no longer claims to know whether it is still alive.

Norway's entry described the 2025 drug reform as an agreement between parties. It had already passed the Storting and been promulgated in June 2025, and it is waiting on the King to bring it into force. It keeps the ban in place.

Peru's entry cited a version of the penal code article that had been replaced twice since. The current text is now cited from the official gazette. The list of drugs with a personal-use exemption still does not include psilocybin, so the status is unchanged.

Portugal's entry pointed at a dead source. The law itself has now been read from the official gazette, which confirms the 2001 start date and that cultivation is still a crime. The entry also now says plainly that this is a general all-drug law that never mentions psilocybin.

Switzerland's entry now reports 686 exceptional authorisations for 2024, 322 of them for psilocybin, citing the Federal Office of Public Health's own figures. It no longer describes these as patients: an authorisation runs about twelve months, covers several treatments and includes continuations of an existing therapy.

Uruguay's entry credited the wrong law with the current wording of the drug-possession article; it was last rewritten in 2020, not 1998. The entry now also records the penalty range and notes that the article's only quantity limit applies to marijuana. The status is unchanged.

Arizona's pending-bill list named two bills that turned out to be about voter registration and residential property. Corrected against the legislature's own bill texts. The law itself is unchanged.

Connecticut's expanded pilot program took effect on 1 July 2026, not on the June signing date the entry previously showed. Corrected from the text of the act.

Indiana's research fund was paid for by the biennial state budget, not by the standalone bill the entry credited, and the fund now covers ibogaine as well as psilocybin. Corrected from the legislature's own records.

Maine's entry cited the wrong bill paper in the wrong Legislature, and still listed a dead bill as pending. Both fixed, and the law that actually prohibits possession is now named.

A note in Michigan's entry described an old decriminalization bill as an Oregon-style licensing bill and put it in the wrong session. Corrected against the legislature's record.

Mississippi's entry no longer lists the state's 2026 ibogaine research law as pending. It was signed in March 2026 and takes effect on 1 July 2026, and no psilocybin measure is pending.

Missouri's entry now says plainly what happened to the psilocybin study bill. It passed the House in April 2026, sat on the Senate's informal calendar from 7 May, and was never truly agreed before the session ended.

New Hampshire's entry no longer lists HB 1772 as pending. It became law in 2026 as Chapter 333, it covers prescribing ibogaine for investigational use, and no psilocybin measure was enacted. Psilocybin is still a controlled drug in New Hampshire.

Texas's entry no longer carries an effective date. Texas has no psilocybin access law, so there is no date to give; the prohibition and the ibogaine research programme are unchanged.

The British Virgin Islands entry pointed at the wrong schedule. The controlled-drug list is Schedule 2, and psilocin sits in its Class A part. The statute was read this time from the government's own live copy.

Poland's entry said the 2005 drug Act lists psilocybin. The Act's annexes have been repealed and the list now lives in a health ministry regulation, which the entry now cites. A separate amendment to that Act was signed in July 2026; it deals with treatment and procedure and leaves the possession offence and the substance lists alone.

Greece's entry named a drug code that was repealed in 2013. The operative law is Law 4139/2013, and the entry now cites it, along with the schedule that still names psilocybin and psilocin. Nothing about the legal status changed.

Canada's record said there were no bills before Parliament. There is one: C-286, a private member's bill introduced on 16 June 2026 that would allow psilocin and psilocybin to be used for medical treatment. It is not scheduled for debate, and the entry now says so.

California's record now lists SB 1224, the Emerging Therapies Research Partnership Act, which names psilocybin among the emerging therapies a state research fund would support in federally registered trials, with a veterans focus. The bill was held in the Assembly Appropriations suspense file on 13 Aug 2026.

Colombia's entry now cites the Constitutional Court's 1994 judgment directly and dates it 5 May 1994. The rewritten summary explains that no statutory quantity covers psilocybin and that police fines for personal-dose possession ended in December 2023.

Costa Rica's entry now cites Ley 8204 itself and dates its effect to 11 January 2002. The rewritten summary explains that the line between lawful possession and trafficking is a purpose test decided case by case rather than a quantity threshold.

Italy's entry now cites the consolidated Testo Unico directly. The summary lists what article 75 actually reaches and what it suspends, and treats quantity as a circumstance courts weigh rather than a line that decides the case.

Slovenia's entry now cites the classification decree annex directly and corrects the penalty description: a fine and up to thirty days, five for a small quantity, with articles 186 and 187 stated separately.

Spain's entry no longer calls small quantities legal. It describes the public-place administrative fine under Ley Organica 4/2015 and keeps personal consumption outside the criminal code, now citing the consolidated Penal Code as well.

This entry now carries much lower confidence. The licence scheme it describes comes from company announcements, and no government source for it has been found.

Australia's entry no longer calls the country the first to regulate psilocybin. It now says what the rule does instead: an authorised psychiatrist may prescribe it for treatment-resistant depression.

Germany's entry now describes how its compassionate use programme actually works. A sponsor notifies the regulator, which confirms the notification rather than granting an approval, and the confirmation has to be renewed each year.

The Bahamas is now recorded as illegal. A 2024 government order brought psilocybine under the Dangerous Drugs Act, and our earlier reading came from a 2017 version of the Act that predates it.

Canada's record now carries a date it was missing: the exemption that links psilocybin to the Special Access Program is revoked on October 1, 2026, when new regulations take effect.

Czechia's record drops an unsupported claim to be Europe's first such framework, and now states the three conditions the regulation actually names.

Maryland's record now explains something it never said: the state's drug law does not govern the clinical trials that run there. Those answer to federal regulators.

Northampton's date moves from March 18 to April 1, 2021. The city council gave the resolution a first reading in March and adopted it on the second reading two weeks later. Somerville's January 14, 2021 date and Cambridge's February 3, 2021 date were checked against city records and are unchanged. All eight Massachusetts municipal dates now come from municipal records.

Argentina's drug statute still criminalizes possession while courts apply the 2009 personal-use doctrine case by case. Nothing is pending, and the record now cites the law itself.

Alaska's psychedelics ballot initiative is listed as active by the Division of Elections, with petition booklets circulating and a September 2026 filing deadline. The record previously called it failed.

Colorado now lists 47 licensed healing centers as of July 31, 2026, per the state's Natural Medicine Division.

Georgia's veterans psychedelic pilot bill died at adjournment, and a bill number long recorded beside it turned out to be a court-fee act. Nothing is pending; the state's two 2026 psychedelic laws stand.

Hawaii's bill to create a psychedelics study task force died in conference committee at the end of the 2026 session. Nothing is pending.

Illinois's verification marker now reflects the July 2026 re-review, which confirmed the record against the legislature's own status pages.

Iowa's medical psilocybin bill died on the Senate calendar two days before adjournment, after passing the House 84 to 6. Nothing is pending.

Kansas's FDA-trigger psilocybin bill died on the House calendar on Turnaround Day in February, and the legislature has adjourned. Nothing is pending.

Kentucky's 2026 session ended with no psilocybin bill. Nothing is pending.

Maryland's ibogaine research bills died at adjournment and nothing is pending. The state's psychedelics task force now runs through 2027, with a report due this October.

Eight Massachusetts cities and towns have adopted resolutions making enforcement of psilocybin laws a low local priority, three more than this record named. Salem's is dated June 8, 2023, when the City Council adopted a revised resolution after the Acting Mayor vetoed the original.

Rhode Island's record now lists H 7925 as pending. The committee's own 2026 agendas show it was never scheduled for a hearing.

Virginia's trigger laws are now recorded as signed on April 6, 2026, per the legislature's own bill histories.

An Irish Seanad bill to decriminalise personal drug possession is at committee stage, and the record now names it. Psilocybin's controlled status is unchanged.

Estonia's recorded maximum fine for small-quantity possession is corrected to 300 fine units, and the record now cites the law itself.

Latvia's record now cites the exact law that makes small-amount possession an administrative offence. The status itself is unchanged.

Ukraine's record now reflects the 2023 reform: first-time possession above the small-amount threshold is punished without imprisonment. Small amounts stay an administrative offence.

The Massachusetts House voted 148 to 2 for a bill carrying a supervised psilocybin pilot. The Senate removed the pilot and the bill is now in conference.

Minnesota's record now lists three more psilocybin bills from the 2026 session. None passed, and the session adjourned in May 2026.

New Mexico's record no longer says $4 million was appropriated for the medical psilocybin program. The enacted act creates two funds that the legislature funds separately.

Rhode Island's pending bill list is cleared. H 7756 was withdrawn in April 2026, and a parallel bill introduced in February 2026 is recorded in the summary.

South Dakota's record no longer lists its enacted trigger law as pending. The law turns on FDA approval alone, not on any DEA action.

Virginia's psilocybin trigger laws are recorded as chapters 305 and 306 and have been in force since July 1, 2026. The trigger has not fired and psilocybin stays in Schedule I.

Washington's record now cites the 2023 session law itself. That act was a partial veto which struck the advisory board and the health department's rulemaking authority, and it took effect July 23, 2023.

West Virginia's pending bill list is cleared. HB 4626 was vetoed and SB 906 is already enacted as the state's trigger law.

Armenia is now recorded as mixed. Small amounts are an administrative offense, while larger quantities remain a criminal offense.

Croatia's record now cites the official gazette. The decriminalized status is unchanged.

Oregon's pending bill list is cleared. HB 4040 is enacted and HB 4110 died in committee.

The supporting citation for HB 2218 moves from a bill-tracking site to the Kansas Legislature's own note on the bill. We use trackers to find bills and official pages to say what they contain.

The entry now cites Montana's own Schedule I listing at section 50-32-222 rather than a bill-tracking page. State records confirm LC 1208 was the draft number for HB 955.

The entry had linked to a bill-tracking site. It now links to the Rhode Island General Assembly's own text of H 7756. Trackers are useful for finding a bill; the legislature is what we cite.

Argentina was moved out of the decriminalized column. The statute still makes possession a crime, and the Supreme Court's 2009 ruling is applied case by case rather than across the board.

Austria was filed as having decriminalized possession. It has not: possession is a criminal offense that prosecutors may divert into probation and treatment, and the status was corrected to illegal.

Belgium was listed as decriminalized and it is not. The 1921 law itself puts possession at three months to five years in prison, so the status was corrected to illegal.

Bolivia had been recorded as legal on the strength of an entry that was actually about ayahuasca. Ley 1008 lists psilocybin, and the status was corrected to illegal.

Brazil had been recorded as legal. It is not. Psilocybin and psilocin are prohibited under Lista F2 of Portaria 344/1998, the mushrooms themselves are unlisted, and the courts are split on what that means, so the status is corrected to mixed.

Colombia's status was confirmed, and the entry gained the three instruments that actually produce it: the 1994 judgment, the 2012 judgment that kept the trafficking offense alive, and the December 2023 repeal of the police fines for personal-dose possession.

Croatia's decriminalization dates from when the amendments took effect on 1 January 2013, not from the December day parliament passed them. The date shown is corrected.

Czechia's prescribing scheme was confirmed in force from 1 Jan 2026, and the entry now cites the act and the December 2025 decree that create it. The first treatments were expected in the second half of 2026.

Denmark had been recorded as mixed, which overstated the position. Possession is criminal, the only exceptions are for research, and no medical program exists, so the status moves to illegal.

Ecuador's entry rested on quantity tables that had already been repealed in November 2023. Consumption is still constitutionally protected, but with no threshold left, possession is judged case by case, so the status moved to mixed.

Finland had been marked mixed, on the strength of an unsettled question about ayahuasca. That says nothing about psilocybin, which is a criminal narcotics offense in Finland, so the status is corrected to illegal.

France was filed as having decriminalized drug use. The fine police can issue on the spot is a criminal penalty for a criminal offense, and a law of June 2025 hardened enforcement, so the status was corrected to illegal.

Iceland had been recorded as mixed on the theory that freshly picked mushrooms fell outside the ban. Regulation 233/2001 draws no such line, so the status was corrected to illegal.

Israel's entry claimed a medical route that does not exist. Psilocybin is approved for no indication there and reachable only through clinical trials, so the status was corrected to illegal.

Lithuania had been listed as decriminalized. Since 2017 possessing even a small quantity has been a criminal matter under Article 259(2) of the Criminal Code, so the status is corrected to illegal.

Mexico's small-quantity rule works off a dose table that leaves psilocybin out. Possession still carries four to seven and a half years, with one narrow exemption for indigenous and Afro-Mexican ceremonies, so the status moved from decriminalized to illegal.

New Zealand had been recorded as decriminalized, which was wrong: psilocybin is a Class A drug. The status was corrected to medical because Medsafe began approving individual prescribers in 2025.

North Macedonia had been listed as decriminalized. Drug use is a fine-only misdemeanor there, but possession is treated as criminal and is prosecuted in practice, and the available sources contradict each other on where the line sits. The status is changed to mixed.

Norway's entry described a reform as pending. Parliament voted the decriminalization bill down in June 2021 and the 2025 reform keeps the ban in place, so the status was corrected to illegal.

Peru had been recorded as legal, which was wrong. The personal-use exemption in article 299 does not name psilocybin, and the cultural-heritage declaration covers ayahuasca and nothing else, so the status was corrected to illegal.

St. Vincent and the Grenadines had been recorded as legal. What is described is a licensing scheme for medicinal and research use, not a general legalization, so the status was narrowed to medical.

Sweden had been recorded as decriminalized. The Narkotikastrafflag makes personal use itself a crime, so the status was corrected to illegal.

Uruguay had been recorded as legal, which overstated it. Personal-use possession is exempt from liability under article 31 of Decreto-Ley 14.294, but sale and production are still crimes, so the status moves to decriminalized.

A task force report and a ballot campaign are not a law. Alaska has enacted nothing, and the entry was corrected from mixed to illegal.

Arizona's entry was missing SB 1555, a 2025 law that would let psilocybin be prescribed only if the FDA approves it first. The 2026 bills stalled and nothing new was enacted.

Florida had been marked mixed. Nothing in the record pulls the other way: possession is a felony and the state tightened the law again in 2025, so the status is corrected to illegal. No reform moved in 2026.

Georgia's two 2026 psychedelic laws do not let anyone use psilocybin: one waits on federal approval, the other regulates clinics. The entry now reads illegal.

Hawaii moves from mixed to illegal. Everything the state has done is a study or a task force, and no access or decriminalization measure has been enacted.

Illinois had been recorded as mixed. Its only psilocybin activity is an advisory board bill and a stalled CURE Act, neither enacted, so the status moved to illegal.

Indiana had been marked mixed. The only thing the state has enacted is a research fund, which pays for studies and opens no route for patients, so the status is corrected to illegal.

Both of Iowa's psilocybin bills failed, one by veto in 2025 and one for want of a Senate vote in May 2026. With nothing enacted, the entry was corrected from mixed to illegal.

Kansas moves from mixed to illegal. Its only psilocybin bill, which depended on a future FDA approval, stalled on the House calendar and died without becoming law.

Kentucky had been recorded as mixed on the strength of a law that is about ibogaine, not psilocybin. Senate Bill 77 changes nothing for psilocybin, so the status was corrected to illegal.

Maine had been marked mixed on the strength of a decriminalization bill. LD 1034 failed its final enactment votes and died on June 10, 2025, so the status is corrected to illegal.

The only psychedelics measure Maryland has enacted extends a task force. That is not access, and the entry was corrected from mixed to illegal.

Mississippi's two 2026 laws leave psilocybin where it was: one funds ibogaine trials, the other takes effect only if the federal government moves first. The status is corrected from mixed to illegal.

Missouri's psilocybin bills all stopped at the study stage, and the fate of the one the House passed in April 2026 was still unresolved at the time. The entry was corrected from mixed to illegal.

Montana moves from mixed to illegal. The only activity on record is HB 955, defeated in committee in 2023, and the legislature does not sit in regular session in 2026.

Nevada had been recorded as mixed on the strength of a working group that only studies the question. With the AB 378 pilot dead at the end of the 2025 session, nothing enacted opens access, so the status moved to illegal.

Every New Hampshire reform bill of 2025 and 2026 is dead. HB 528 was tabled in June 2025, HB 1796 was killed in February 2026, and the Senate killed HB 1809 on May 5, 2026. The status is corrected from mixed to illegal.

New Jersey's hospital pilot was confirmed, and the signing date was corrected from 16 January to 20 January 2026.

New York had been recorded as mixed because reform bills exist. None of them has had a committee vote, and a pending bill changes no law, so the status was corrected to illegal.

North Carolina had been recorded as mixed. SB 568 was a study bill and it died at the May 2025 crossover deadline, so the status moved to illegal.

Nothing enacted, no city measure, and no bill moving in the current General Assembly. Ohio's entry was corrected from mixed to illegal.

Oklahoma moves from mixed to illegal. The only psychedelics law enacted in 2026 covers ibogaine, and no psilocybin bill was enacted.

Pennsylvania had been recorded as mixed. SB 1149 has never left the committee it was referred to and the older research bills are dead, so the status moved to illegal.

Rhode Island had been marked mixed. H 7756 was withdrawn at its sponsor's request on April 9, 2026 and nothing has been enacted, so the status is corrected to illegal.

South Dakota moves from mixed to illegal. HB 1099 was signed in March 2026, but its carve-out only applies once the FDA approves a psilocybin product, so it grants no access today.

Tennessee had been recorded as mixed on the basis of a law that names only ibogaine. No psilocybin legislation exists in the state, so the status was corrected to illegal.

Texas had been recorded as mixed because the state funds psychedelic research. Funding is not access, so the status moved to illegal. SB 2308's effective date was corrected to 11 June 2025, and the state announced in March 2026 that it would run the ibogaine trials itself.

Utah's entry now records HB 390 (2026), which authorizes a study of psychedelic-assisted therapy for veterans, and the effective date of the 2024 clinical authorization is corrected to May 1, 2024. The status is unchanged.

Vermont's own advisory group recommended against creating a program, and the bill that followed it never moved. The listing changed from mixed to illegal.

Virginia moves from mixed to illegal. Its two trigger laws were enacted in April 2026 but stay dormant until the FDA approves a psilocybin product, and a separate bill to create an advisory council, SB 1101, was killed in the House.

West Virginia had been recorded as mixed. SB 906 is enacted but does nothing until the FDA acts, HB 4626 was vetoed, and a third bill had been listed under the wrong number, so the status moved to illegal.

The DC entry carried the wrong law number and the wrong effective date. It is D.C. Law 23-268, effective 16 March 2021. The status itself was confirmed.

The British Virgin Islands had been recorded as legal, which the statute does not support: it schedules psilocin and its esters and makes possession an offence. The gap around unlisted fresh mushrooms is real, so the status moved to mixed.

Tennessee's entry now records that the ibogaine HOPE Treatment Act was signed on 22 May 2026 and became Public Chapter 1119. It does not concern psilocybin, whose status is unchanged.

Oklahoma's entry now records the ibogaine Breakthrough Therapy Act as enacted rather than pending, and cites the enrolled text of the act. Psilocybin's status is unchanged.

Utah's entry now records the 2026 scheduling act that would follow a federal rescheduling of an approved psilocybin medicine, and corrects the description of the veterans research law, which authorizes a study but appropriates no money itself.

Pennsylvania's entry now records both psilocybin bills before the General Assembly, HB 1439 as well as SB 1149. Neither has moved and the legal position is unchanged.

Vermont's entry now records all three psychedelic bills before the General Assembly, and cites the statute that prohibits psilocybin rather than the advisory working group. Nothing in Vermont law has changed.